Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Overview of Trevi Therapeutics, Inc.
Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company dedicated to transforming treatment paradigms for chronic cough and pruritic conditions. The company is deeply involved in the research and development of Haduvio™, an innovative oral extended-release formulation of nalbuphine. Harnessing a unique dual mechanism of action, Haduvio functions as a kappa-opioid receptor agonist and a mu-opioid receptor antagonist. This dual action is central to its potential to provide symptomatic relief in conditions characterized by chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), as well as in dermatologic disorders such as prurigo nodularis.
Scientific and Clinical Rationale
The core of Trevi's approach lies in addressing a significant unmet medical need. In diseases like IPF and RCC, chronic cough is not only debilitating but also correlates with a decline in patients' overall quality of life. Haduvio’s design specifically targets the cough reflex arc through both central and peripheral pathways. By modulating opioid receptors, its mechanism aims to reduce cough frequency and severity without the inherent risks associated with conventional opioid therapies. The investigational therapy is grounded in robust clinical research, with various ongoing trials designed to ascertain its efficacy, safety, and optimal dosing across multiple patient subgroups.
Clinical Development and Research Programs
Trevi Therapeutics is rigorously evaluating Haduvio in numerous clinical settings. The company has instituted several trials, including randomized controlled studies, to evaluate the therapy's impact on 24-hour cough frequency and associated patient-reported outcomes. Key studies include Phase 2a and Phase 2b trials that measure objective cough metrics and patient quality of life indicators. These trials are meticulously designed with endpoints that evaluate both clinical efficacy and potential safety considerations, such as the abuse potential of nalbuphine. Through its comprehensive clinical program, Trevi is focused on gathering robust data that can support regulatory submissions and ultimately provide an alternative treatment where no approved therapies currently exist.
Market Position and Unmet Needs
Chronic cough in IPF and RCC represents a significant area of concern due to the absence of approved treatments in many regions. Trevi Therapeutics positions itself within this niche by offering a therapy that directly targets the underlying physiological mechanisms of cough hypersensitivity. With millions of potential patients and a high prevalence of chronic cough in affected populations, the company addresses the dual challenges of efficacy and patient tolerability using an innovative formulation. This strategic focus on a high unmet need segment bolsters its potential market significance and underscores its commitment to advancing medical science in a challenging therapeutic area.
Operational Excellence and Strategic Considerations
Trevi Therapeutics exhibits a robust operational framework, integrating advanced clinical trial methodologies and state-of-the-art pharmaceutical research. The company's structured approach to trial design, endpoint assessment, and safety evaluation reinforces its authority in the biopharmaceutical domain. Its strategy reflects a nuanced understanding of both the clinical and commercial landscapes, ensuring that scientific precision is coupled with a patient-centric focus. By emphasizing rigorous research, clear strategic milestones, and targeted clinical endpoints, Trevi demonstrates a balanced and expert approach to innovation in therapeutic development.
Conclusion
In summary, Trevi Therapeutics is a forward-thinking clinical-stage biopharmaceutical enterprise poised to redefine treatment standards for chronic cough and pruritic conditions. Through the development of Haduvio™, the company leverages sophisticated pharmacological mechanisms to address significant clinical challenges and empower patients with limited treatment options. Its commitment to comprehensive research, detailed clinical evaluation, and operational excellence cements its role as a critical player in the evolving landscape of respiratory and dermatologic therapeutics.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, featuring a virtual fireside chat at 4:20 p.m. ET. The event will also include virtual investor meetings. Live webcasts can be accessed on the company's website, with a replay available for 30 days post-conference. Trevi is focused on the development of Haduvio (nalbuphine ER) for treating serious neurologically mediated conditions, including chronic cough and pruritus, currently conducting clinical trials for these indications.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announces the appointment of William Forbes as Chief Development Officer, effective immediately. Dr. Forbes, a seasoned professional with over 30 years in pharmaceutical product development, will oversee the clinical development of Haduvio™ (nalbuphine ER) for conditions like chronic pruritus and cough. Forbes previously held leadership roles at Vivelix Pharmaceuticals and Salix Pharmaceuticals, contributing to 12 FDA approvals. Trevi aims to fulfill unmet medical needs through Haduvio, currently in late-stage clinical trials.
Trevi Therapeutics (TRVI) reported updates on its clinical trials and financial results for Q3 2020. The PRISM trial for Haduvio, targeting severe pruritus, has surpassed halfway enrollment with approximately 190 subjects. The company aims to complete enrollment by Q3 2021 and report data by Q4 2021. In a phase 2 trial for chronic cough in IPF, new patient enrollment has resumed post COVID-19. As of September 30, 2020, Trevi's cash position was $53.3 million, expected to fund operations into H1 2022, with a Q3 net loss of $7.4 million.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 10:00 a.m. ET. The management will provide a company overview and conduct virtual investor meetings. Interested parties can access a live webcast of the presentation on Trevi's website, with an archived replay available for 30 days post-conference. Trevi Therapeutics focuses on developing Haduvio™, an investigational oral formulation of nalbuphine, aimed at treating serious neurologically mediated conditions like chronic pruritus.
Trevi Therapeutics (Nasdaq: TRVI) announces a conference call on November 11, 2020, at 4:30 p.m. ET to discuss Q3 2020 financial results and provide a corporate update. The call can be accessed by phone or via a live audio webcast on the company's website. Haduvio™ (nalbuphine ER), the company's lead drug, is being developed for serious neurologically mediated conditions, including chronic pruritus and levodopa-induced dyskinesia. Currently, Trevi is conducting a Phase 2b/3 trial, PRISM, for patients with severe pruritus.
Trevi Therapeutics, Inc. (TRVI) has resumed patient screening for its Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) after a pause due to COVID-19. The trial aims to enroll 60 subjects and investigate the efficacy of nalbuphine ER in reducing cough frequency. Additionally, the Phase 2b/3 PRISM trial for Haduvio in severe pruritus has reached 50% enrollment, with expectations to finish by Q3 2021 and report data by Q4 2021. The regulatory approval for protocol amendments enhances patient safety during the pandemic.
Trevi Therapeutics Updates Management Team
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced key appointments to enhance its clinical development and commercialization strategies for Haduvio™. Shashank Rohatagi, Ph.D. becomes Vice President of Pharmacology; Farrell Simon, Pharm.D. leads U.S. marketing; and Katherine S. Takaki, Ph.D. oversees global regulatory affairs. Dr. Rohatagi brings extensive regulatory experience, Dr. Simon has a strong commercial background from Pfizer, and Dr. Takaki has a proven record in regulatory strategy. Together, they aim to advance Haduvio’s development for serious conditions.
Trevi Therapeutics, a clinical-stage biopharmaceutical company focused on Haduvio (nalbuphine ER), announced its presentation at the 2020 H.C. Wainwright Global Investment Conference on September 16, 2020, at 3:00 p.m. ET. The presentation will outline the company’s development of Haduvio for conditions like chronic pruritus and chronic cough. A live webcast will be available on their website, with an archived version accessible for 30 days.
Trevi Therapeutics (Nasdaq: TRVI) announced a positive outcome in its PRISM trial following a sample size re-estimation, increasing target enrollment from 240 to 360 subjects. With COVID-19 restrictions lifted, patient enrollment has accelerated, and approximately 155 subjects have been recruited. The company secured a $14 million term loan to support operations into the first half of 2022. For Q2 2020, Trevi reported a net loss of $7.4 million, with cash and cash equivalents at $44.2 million, down from $57.3 million at year-end 2019.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will participate in the virtual 2020 BTIG Biotechnology Conference on August 10, 2020. Management will engage in a fireside chat at 11:00 a.m. ET, and virtual investor meetings will be hosted. Attendees can access a live webcast on the company’s website, with an archive available for 30 days post-conference. Trevi focuses on developing Haduvio™ (nalbuphine ER) for treating chronic pruritus, chronic cough in idiopathic pulmonary fibrosis patients, and levodopa-induced dyskinesia. Currently, it is in a Phase 2b/3 clinical trial for severe pruritus.